Sarah Cannon Research Institute

LINKER-AL2 shows linvoseltamab delivers rapid, deep responses in relapsed AL amyloidosis, addressing major unmet need with off-the-shelf access and a manageable safety profile.

Early data for LINKER-AL2 show linvoseltamab drives rapid and deep responses following relapse after frontline treatment for AL amyloidosis, which has no approved therapies.

The FDA announcement seeks nominees from the public for drug repurposing, leveraging AI signals to expand treatment options for rare diseases and other unmet needs.

Mosunetuzumab, a bispecific, plus polatuzumab vedotin, an antibody-drug conjugate, deliver high response rates in relapsed MCL, potentially enabling outpatient community oncology treatment and wider patient access.

The FDA now permits outpatient monitoring for epcoritamab’s first full dose in R/R DLBCL, as EPCORE-NHL-6 data support safe bispecific antibody access.

Interim data from the EPCORE-NHL-6 trial show safety outcomes similar to those in the pivotal trial that led to approval for the bispecific T-cell–engaging antibody.

The originator of the phase 1 drug development program at Sarah Cannon Research Institute reflects on his career.

New leaders of the Sarah Cannon Research Institute discuss its mission and priorities amid a changing landscape in community oncology.

A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment.

Explore the latest advancements in oncology, including biomarkers and targeted therapies, enhancing patient care at Tennessee Oncology and Vanderbilt-Ingram Cancer Center.

A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.

Studies presented at ASCO reveal promising treatments for triple-negative and ER-positive breast cancer, highlighting the benefits of sacituzumab govitecan and vepdegestrant.

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven therapies, revolutionizing cancer treatment and diagnostics.

Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor natural killer (CAR NK) cell therapy. Toxicity with this therapy is lower than seen in many conventional CAR T-cell therapies.

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.